DOP2011000067A - Derivados de picolinamida como inhibidores de cinasa - Google Patents
Derivados de picolinamida como inhibidores de cinasaInfo
- Publication number
- DOP2011000067A DOP2011000067A DO2011000067A DO2011000067A DOP2011000067A DO P2011000067 A DOP2011000067 A DO P2011000067A DO 2011000067 A DO2011000067 A DO 2011000067A DO 2011000067 A DO2011000067 A DO 2011000067A DO P2011000067 A DOP2011000067 A DO P2011000067A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- compositions
- kinase
- compounds
- formula
- new compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Abstract
Se proporcionan nuevos compuestos de fórmula II: y composiciones. En ciertas modalidades, los compuestos y composiciones cumplen la función de ser efectivos en la inhibición de la actividad de cuando menos una cinasa Maloney de integración del provirus (Cinasa PIM) asociada con tumorgénesis. Los nuevos compuestos de fórmula II y composiciones se pueden utilizar ya sea solos o bien en combinación con cuando menos un agente adicional para el tratamiento de un trastorno mediado por una cinasa de serina/treonina o por un receptor de cinasa de tirosina, tal como cáncer incluyendo malignidades hematopoyéticas, carcinomas, melanoma, trastornos mieloides, adenomas, sarcomas, enfermedades autoinmunes, reacciones alérgicas, y en los síndromes de rechazo de trasplantes de órganos. Un ejemplo de los compuestos de picolinamida desarrollados es el siguiente:
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9366608P | 2008-09-02 | 2008-09-02 | |
US22566009P | 2009-07-15 | 2009-07-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2011000067A true DOP2011000067A (es) | 2017-01-15 |
Family
ID=41228825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2011000067A DOP2011000067A (es) | 2008-09-02 | 2011-03-02 | Derivados de picolinamida como inhibidores de cinasa |
Country Status (39)
Country | Link |
---|---|
US (4) | US8329732B2 (es) |
EP (1) | EP2344474B1 (es) |
JP (2) | JP5412519B2 (es) |
KR (1) | KR101345920B1 (es) |
CN (3) | CN102203079B (es) |
AU (1) | AU2009289319C1 (es) |
BR (1) | BRPI0918268B1 (es) |
CA (1) | CA2734415C (es) |
CL (1) | CL2011000454A1 (es) |
CO (1) | CO6351725A2 (es) |
CR (1) | CR20110114A (es) |
DK (1) | DK2344474T3 (es) |
DO (1) | DOP2011000067A (es) |
EA (1) | EA020136B1 (es) |
EC (1) | ECSP11010859A (es) |
ES (1) | ES2551900T3 (es) |
GE (1) | GEP20135849B (es) |
HK (2) | HK1156627A1 (es) |
HN (1) | HN2011000629A (es) |
HR (1) | HRP20151410T1 (es) |
HU (1) | HUE026381T2 (es) |
IL (1) | IL211291A (es) |
MA (1) | MA32684B1 (es) |
ME (1) | ME01291A (es) |
MX (1) | MX2011002365A (es) |
MY (1) | MY150136A (es) |
NI (1) | NI201100052A (es) |
NZ (1) | NZ591449A (es) |
PE (1) | PE20110298A1 (es) |
PL (1) | PL2344474T3 (es) |
PT (1) | PT2344474E (es) |
RS (1) | RS54506B1 (es) |
SI (1) | SI2344474T1 (es) |
SM (1) | SMT201600005B (es) |
SV (1) | SV2011003849A (es) |
TW (1) | TWI434843B (es) |
UY (1) | UY32085A (es) |
WO (1) | WO2010026124A1 (es) |
ZA (1) | ZA201101118B (es) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY162590A (en) | 2005-12-13 | 2017-06-30 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors |
US20140249135A1 (en) * | 2007-03-01 | 2014-09-04 | Novartis Ag | Pim kinase inhibitors and methods of their use |
EP3495369B1 (en) | 2007-06-13 | 2021-10-27 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
PT2344474E (pt) | 2008-09-02 | 2015-12-28 | Novartis Ag | Derivados de picolinamida como inibidores de cinase |
EP2342190A1 (en) * | 2008-09-02 | 2011-07-13 | Novartis AG | Bicyclic kinase inhibitors |
MX2011012262A (es) | 2009-05-22 | 2012-01-25 | Incyte Corp | 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il] octano-o heptano-nitrilo como inhibidores de cinasas janus (jak). |
EA025520B1 (ru) | 2009-05-22 | 2017-01-30 | Инсайт Холдингс Корпорейшн | N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ |
TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
SI3354652T1 (sl) | 2010-03-10 | 2020-08-31 | Incyte Holdings Corporation | Derivati piperidin-4-il azetidina kot inhibitorji JAK1 |
EP2556066B1 (en) * | 2010-04-07 | 2016-10-19 | F.Hoffmann-La Roche Ag | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
SG10201910912TA (en) | 2010-05-21 | 2020-01-30 | Incyte Corp | Topical Formulation for a JAK Inhibitor |
WO2012004217A1 (en) * | 2010-07-06 | 2012-01-12 | Novartis Ag | Cyclic ether compounds useful as kinase inhibitors |
BR112013012502A2 (pt) | 2010-11-19 | 2019-03-06 | Incyte Corporation | pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
US9284270B2 (en) | 2011-02-14 | 2016-03-15 | The Governers Of The University Of Alberta | Boronic acid catalysts and methods of use thereof for activation and transformation of carboxylic acids |
JP2014506915A (ja) * | 2011-03-04 | 2014-03-20 | ノバルティス アーゲー | キナーゼ阻害剤としての四置換シクロヘキシル化合物 |
UY33930A (es) * | 2011-03-04 | 2012-10-31 | Novartis Ag | Inhibidores novedosos de quinasas |
MX2013012661A (es) | 2011-04-29 | 2014-03-27 | Amgen Inc | Compuestos de piridazina biciclicos como inhibidores pim. |
MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
ES2671748T3 (es) | 2011-07-21 | 2018-06-08 | Tolero Pharmaceuticals, Inc. | Inhibidores heterocíclicos de proteína quinasas |
US9458151B2 (en) * | 2011-08-11 | 2016-10-04 | Jikai Biosciences, Inc. | Isothiazole derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof |
US9453003B2 (en) * | 2011-08-11 | 2016-09-27 | Jikai Biosciences, Inc. | Pyrimidine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
WO2013175388A1 (en) * | 2012-05-21 | 2013-11-28 | Novartis Ag | Novel ring-substituted n-pyridinyl amides as kinase inhibitors |
WO2014033631A1 (en) | 2012-08-31 | 2014-03-06 | Novartis Ag | N-(3-pyridyl) biarylamides as kinase inhibitors |
WO2014033630A1 (en) | 2012-08-31 | 2014-03-06 | Novartis Ag | Novel aminothiazole carboxamides as kinase inhibitors |
PL2900657T3 (pl) | 2012-09-26 | 2020-07-27 | F.Hoffmann-La Roche Ag | Cykliczne związki eterowe pirazol-4-ilo-heterocyklilo-karboksyamidu i sposoby stosowania |
CN103724301A (zh) * | 2012-10-10 | 2014-04-16 | 上海特化医药科技有限公司 | (2r)-2-脱氧-2,2-二取代-1,4-核糖内酯及其制备方法和用途 |
SG11201503695XA (en) | 2012-11-15 | 2015-06-29 | Incyte Corp | Sustained-release dosage forms of ruxolitinib |
US20150336960A1 (en) | 2012-12-19 | 2015-11-26 | Novartis Ag | Aryl-substituted fused bicyclic pyridazine compounds |
JP6437452B2 (ja) * | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
ME03780B (me) | 2013-01-15 | 2021-04-20 | Incyte Holdings Corp | Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze |
EA030705B1 (ru) | 2013-03-06 | 2018-09-28 | Инсайт Холдингс Корпорейшн | Способы и промежуточные соединения при получении ингибитора jak |
US9113629B2 (en) * | 2013-03-15 | 2015-08-25 | Dow Agrosciences Llc | 4-amino-6-(4-substituted-phenyl)-picolinates and 6-amino-2-(4-substituted-phenyl)-pyrimidine-4-carboxylates and their use as herbicides |
ES2792549T3 (es) | 2013-08-07 | 2020-11-11 | Incyte Corp | Formas de dosificación de liberación sostenida para un inhibidor de JAK1 |
WO2015019320A1 (en) * | 2013-08-08 | 2015-02-12 | Novartis Ag | Pim kinase inhibitor combinations |
WO2015027124A1 (en) | 2013-08-23 | 2015-02-26 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
US20160375024A1 (en) * | 2013-11-27 | 2016-12-29 | Novartis Ag | Combination therapy comprising an inhibitor of jak, cdk, and pim |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
CN106103484B (zh) | 2014-03-14 | 2021-08-20 | 诺华股份有限公司 | 针对lag-3的抗体分子及其用途 |
MX2016012007A (es) | 2014-03-18 | 2016-12-05 | Hoffmann La Roche | Compuestos de oxepan-2-il-pirazol-4-il-heterociclil-carboxamida y metodos de uso. |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
US9993551B2 (en) | 2014-09-13 | 2018-06-12 | Novartis Ag | Combination therapies of EGFR inhibitors |
KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
CU20170052A7 (es) | 2014-10-14 | 2017-11-07 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 |
MY190404A (en) | 2015-03-10 | 2022-04-21 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
SI3317301T1 (sl) | 2015-07-29 | 2021-10-29 | Novartis Ag | Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3 |
AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
CN105254624B (zh) * | 2015-09-18 | 2019-08-09 | 上海吉铠医药科技有限公司 | 异噻唑衍生物pim激酶抑制剂及其制备方法与在制药中的应用 |
CN105130959B (zh) * | 2015-09-18 | 2018-08-03 | 上海吉铠医药科技有限公司 | 嘧啶衍生物pim激酶抑制剂及其制备方法与在制药中的应用 |
TW201718546A (zh) | 2015-10-02 | 2017-06-01 | 英塞特公司 | 適用作pim激酶抑制劑之雜環化合物 |
BR112018008904A2 (pt) | 2015-11-03 | 2018-11-27 | Janssen Biotech Inc | anticorpos que se ligam especificamente a tim-3 e seus usos |
CA3007671A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
CN107522695B (zh) * | 2016-06-21 | 2018-09-14 | 上海方予健康医药科技有限公司 | 一种pim激酶抑制剂的盐酸盐及其制备方法和用途 |
CN107519175A (zh) * | 2016-06-21 | 2017-12-29 | 上海方予健康医药科技有限公司 | 一种嘧啶化合物或其盐在制备用于预防和/或治疗与flt3相关的疾病或障碍的药物中的应用 |
CN107522696B (zh) * | 2016-06-21 | 2019-02-19 | 上海方予健康医药科技有限公司 | 一种嘧啶类化合物的盐酸盐及其制备方法和用途 |
EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
US11236048B2 (en) | 2017-06-30 | 2022-02-01 | Bristol-Myers Squibb Company | Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparation |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
PL3746429T3 (pl) | 2018-01-30 | 2022-06-20 | Incyte Corporation | Procesy do otrzymywania (1-(3-fluoro-2-(trifluorometylo)izonikotynoilo)piperydyn-4-onu) |
ES2910071T3 (es) | 2018-03-08 | 2022-05-11 | Incyte Corp | Compuestos de aminopirazina diol como inhibidores de PI3K-Y |
WO2019191684A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Treatment of hidradenitis suppurativa using jak inhibitors |
US20210113562A1 (en) | 2018-04-13 | 2021-04-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer |
TW202015726A (zh) | 2018-05-30 | 2020-05-01 | 瑞士商諾華公司 | Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法 |
WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
EP3924351A4 (en) | 2019-02-12 | 2022-12-21 | Sumitomo Pharma Oncology, Inc. | FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS |
CN110078706B (zh) * | 2019-05-31 | 2022-02-01 | 浙江师范大学 | 一种伊马替尼衍生物及其制备方法和用途 |
CN110452164B (zh) * | 2019-09-10 | 2022-07-22 | 上海皓鸿生物医药科技有限公司 | Pim447关键中间体的制备方法 |
JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
JP2022553832A (ja) * | 2019-11-07 | 2022-12-26 | クリネティックス ファーマシューティカルズ,インク. | メラノコルチンサブタイプ-2受容体(mc2r)アンタゴニストおよびその使用 |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
CN112915086B (zh) * | 2021-01-27 | 2022-04-12 | 广州市力鑫药业有限公司 | 一种含有Akt靶向激酶抑制剂的药物组合物 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1251134A4 (en) | 2000-01-26 | 2003-01-29 | Meiji Seika Kaisha | NEW CARBAPENEM DERIVATIVES OF THE QUATERNARY SALT TYPE |
EP1257536A1 (en) * | 2000-01-27 | 2002-11-20 | Cytovia, Inc. | Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
US8618085B2 (en) | 2000-04-28 | 2013-12-31 | Koasn Biosciences Incorporated | Therapeutic formulations of desoxyepothilones |
MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
KR100557093B1 (ko) | 2003-10-07 | 2006-03-03 | 한미약품 주식회사 | 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법 |
PE20050444A1 (es) | 2003-10-31 | 2005-08-09 | Takeda Pharmaceutical | Compuestos de piridina como inhibidores de la peptidasa |
JP2007513184A (ja) | 2003-12-04 | 2007-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なキノキサリン |
US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
US20060004197A1 (en) | 2004-07-02 | 2006-01-05 | Thomas Thrash | Sulfonamide-based compounds as protein tyrosine kinase inhibitors |
CR9465A (es) | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
CA2617557A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Benzimidazole derivatives as sirtuin modulators |
WO2007044724A2 (en) | 2005-10-06 | 2007-04-19 | Exelixis, Inc. | Aminopyrimidine, aminopyridine and aniline derivatives inhibitors of pim-i and/or pim-3 |
GB0520657D0 (en) * | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
HRPK20050957B3 (en) * | 2005-11-11 | 2008-09-30 | Džanko Nikša | Collapsible hanger |
CA2668255A1 (en) * | 2006-10-31 | 2008-05-08 | Schering Corporation | Anilinopiperazine derivatives and methods of use thereof |
CN101578275A (zh) * | 2006-10-31 | 2009-11-11 | 先灵公司 | 苯胺基哌嗪衍生物及其使用方法 |
BRPI0808523A2 (pt) * | 2007-03-01 | 2014-08-19 | Novartis Vaccines & Diagnostic | Inibidores de pim cinase e métodos de seu uso |
JP5241834B2 (ja) * | 2007-07-19 | 2013-07-17 | メルク・シャープ・アンド・ドーム・コーポレーション | プロテインキナーゼ阻害剤としての複素環アミド化合物 |
EP2195286A2 (en) | 2007-09-10 | 2010-06-16 | Cipla Limited | Process for the preparation of a raf kinase inhibitor and intermediates for use in the process |
UY31679A1 (es) * | 2008-03-03 | 2009-09-30 | Inhibidores de cinasa pim y metodos para su uso | |
PT2344474E (pt) * | 2008-09-02 | 2015-12-28 | Novartis Ag | Derivados de picolinamida como inibidores de cinase |
US8809380B2 (en) | 2009-08-04 | 2014-08-19 | Raqualia Pharma Inc. | Picolinamide derivatives as TTX-S blockers |
EP2665711A1 (en) | 2011-01-21 | 2013-11-27 | Abbvie Inc. | Picolinamide inhibitors of kinases |
-
2009
- 2009-08-31 PT PT97823967T patent/PT2344474E/pt unknown
- 2009-08-31 PE PE2011000444A patent/PE20110298A1/es active IP Right Grant
- 2009-08-31 EP EP09782396.7A patent/EP2344474B1/en active Active
- 2009-08-31 HU HUE09782396A patent/HUE026381T2/en unknown
- 2009-08-31 DK DK09782396.7T patent/DK2344474T3/en active
- 2009-08-31 ME MEP-2011-37A patent/ME01291A/me unknown
- 2009-08-31 AU AU2009289319A patent/AU2009289319C1/en active Active
- 2009-08-31 KR KR1020117007556A patent/KR101345920B1/ko active IP Right Grant
- 2009-08-31 GE GEAP2009012163 patent/GEP20135849B/en unknown
- 2009-08-31 CA CA2734415A patent/CA2734415C/en active Active
- 2009-08-31 MY MYPI2011000927A patent/MY150136A/en unknown
- 2009-08-31 SI SI200931330T patent/SI2344474T1/sl unknown
- 2009-08-31 CN CN200980143187.8A patent/CN102203079B/zh active Active
- 2009-08-31 BR BRPI0918268-3A patent/BRPI0918268B1/pt active IP Right Grant
- 2009-08-31 MX MX2011002365A patent/MX2011002365A/es active IP Right Grant
- 2009-08-31 CN CN2013102514039A patent/CN103333157A/zh active Pending
- 2009-08-31 JP JP2011524408A patent/JP5412519B2/ja active Active
- 2009-08-31 CN CN201410461060.3A patent/CN104311480A/zh active Pending
- 2009-08-31 EA EA201100425A patent/EA020136B1/ru not_active IP Right Cessation
- 2009-08-31 WO PCT/EP2009/061205 patent/WO2010026124A1/en active Application Filing
- 2009-08-31 RS RS20150730A patent/RS54506B1/en unknown
- 2009-08-31 PL PL09782396T patent/PL2344474T3/pl unknown
- 2009-08-31 US US12/584,158 patent/US8329732B2/en active Active
- 2009-08-31 NZ NZ591449A patent/NZ591449A/xx not_active IP Right Cessation
- 2009-08-31 ES ES09782396.7T patent/ES2551900T3/es active Active
- 2009-09-01 UY UY0001032085A patent/UY32085A/es not_active Application Discontinuation
- 2009-09-01 TW TW098129413A patent/TWI434843B/zh not_active IP Right Cessation
-
2011
- 2011-02-11 ZA ZA2011/01118A patent/ZA201101118B/en unknown
- 2011-02-17 IL IL211291A patent/IL211291A/en active IP Right Grant
- 2011-03-01 NI NI201100052A patent/NI201100052A/es unknown
- 2011-03-01 CL CL2011000454A patent/CL2011000454A1/es unknown
- 2011-03-02 EC EC2011010859A patent/ECSP11010859A/es unknown
- 2011-03-02 HN HN2011000629A patent/HN2011000629A/es unknown
- 2011-03-02 CR CR20110114A patent/CR20110114A/es unknown
- 2011-03-02 DO DO2011000067A patent/DOP2011000067A/es unknown
- 2011-03-03 SV SV2011003849A patent/SV2011003849A/es unknown
- 2011-03-08 CO CO11028419A patent/CO6351725A2/es active IP Right Grant
- 2011-04-01 MA MA33733A patent/MA32684B1/fr unknown
- 2011-10-17 HK HK11111043.1A patent/HK1156627A1/xx not_active IP Right Cessation
- 2011-12-15 US US13/327,358 patent/US8592455B2/en active Active
-
2012
- 2012-03-06 HK HK12102246.4A patent/HK1162022A1/xx not_active IP Right Cessation
-
2013
- 2013-06-25 JP JP2013132978A patent/JP5813701B2/ja active Active
- 2013-11-15 US US14/081,132 patent/US9079889B2/en active Active
-
2015
- 2015-07-13 US US14/797,534 patent/US20150315150A1/en not_active Abandoned
- 2015-12-22 HR HRP20151410TT patent/HRP20151410T1/hr unknown
-
2016
- 2016-01-05 SM SM201600005T patent/SMT201600005B/it unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2011000067A (es) | Derivados de picolinamida como inhibidores de cinasa | |
EA201100426A1 (ru) | Бициклические ингибиторы киназы | |
EA201100427A1 (ru) | Гетероциклические ингибиторы киназы | |
CL2012000324A1 (es) | Compuestos derivados de benciimidazol sustituido con un grupo pirazol sustituido, inhibidor de quinasa fgfr; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
CU23784B7 (es) | Bencimidazoles sustituidos como inhibidores de cinasa | |
NI201000156A (es) | Compuestos heterocíclicos novedosos y usos de los mismos. | |
CL2012000583A1 (es) | Compuestos derivados de quinazolinas sustituidas, inhibidores de los canales ionicos de potasio; composicion farmaceutica que los comprende; uso del compuesto para tratar o prevenir arritmias, controlar la frecuencia cardiaca, entre otras. | |
EA200901144A1 (ru) | Ингибиторы киназы pim и способы их применения | |
CL2009001058A1 (es) | Compuestos derivados de oxazinas sustituidas, inhibidores de la 11b-hidroxiesteroide deshidrogenasa de tipo-1; composicion farmaceutica; y uso del compuesto para inhibir la actividad de 11b-hsd1, como en el tratamiento de la diabetes, dislipidemia, hipertension, obesidad, cancer, glaucoma, entre otras. | |
CL2012000340A1 (es) | Compuestos heterociclicos derivados de pirimidina sustituida; composicion farmaceutica y su uso como inhibidores de quinasas para tratar el cancer tal como carcinoma pulmonar, carcinoma pancreatico, carcinoma de vejiga, carcinoma de colon, trastornos mieloides, cancer de prostata, de tiroides, melanomas, adenomas, cancer de higado. | |
CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. | |
CL2011003147A1 (es) | Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer. | |
CL2019000986A1 (es) | 1,3 di sustituto ciclobutano o derivados de azetidina como inhibidores de prostaglandina d sintasa hematopoyética(h-pgds). | |
ECSP088828A (es) | 4-anilinoquinolina-3-carboxamidas como inhibidores de la quinasa csf-1r | |
CL2011001516A1 (es) | Compuestos derivados de carbazol carboxamida, inhibidores de cinasa; composicion farmaceutica que los comprende ; y su uso en el tratamiento del lupus eritematoso sistemico, artritis reumatoide, esclerosis multiple o rechazo de trasplante | |
CO6400170A2 (es) | Agosnistas y antagonistas del receptor s1p5 y métodos de uso de los mismos | |
CL2007002994A1 (es) | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. | |
EA201290305A1 (ru) | Производные трициклического пиразоламина | |
GT200800158A (es) | Pirazolquinolonas como potentes inhibidores de parp | |
PE20171738A1 (es) | Proceso para la preparacion de antagonistas del receptor androgeno e intermediarios de los mismos | |
CO2024001285A2 (es) | Compuestos tricíclicos como inhibidores de kras | |
MA33059B1 (fr) | Utilisation d'antagonistes des recepteurs nk | |
MA32062B1 (fr) | Sels de triazolium comme inhibiteurs de par1, leur production et leur utilisation comme médicaments | |
GT200500219A (es) | 4-(2,4-dicloro-5-metoxifenil)amino-6-metoxi-7([5-amino-sustituido)metil]-3-furil)-3-quinolincarbonitrilos comoinhibidores de quinasa. | |
CL2011001850A1 (es) | Uso de un compuesto nitrogenado heterociclico sustituido para el tratamiento de cánceres tales como cáncer de colon o mieloma múltiple;composición farmacéutica que comprende al compuesto. |